Find Clinical Trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation


← Back
Study Phase

Phase 3

Therapeutic Area

Cancers

IndicationGlioma
SponsorInstitut de Recherches Internationales Servier
Active substance/
Medical device

vorasidenib

Active Substance CodeAG881
Protocol CodeAG881-C-004
EudraCT Code2019‐002481‐13
NCT CodeNCT04164901
Other Protocol Name :INDIGO


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2023 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility